Ocular Therapeutix™ to Present at Two Investor Conferences in March
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on redefining the retina experience, has announced its participation in two major investor conferences in March 2025.
The company will first attend the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, where Executive Chairman, President and CEO Pravin U. Dugel, MD will participate in a fireside chat at 11:50 AM ET.
Following this, Ocular will join the Leerink Partners Global Healthcare Conference 2025 in Miami Beach on Monday, March 10, 2025, with another fireside chat scheduled for 10:00 AM ET, also featuring Dr. Dugel.
Investors can access live webcasts of both presentations through the Events and Presentations section on the Investor Relations page of the Ocular Therapeutix website.
Ocular Therapeutix (NASDAQ: OCUL), un'azienda biofarmaceutica focalizzata sulla ridefinizione dell'esperienza retinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel marzo 2025.
L'azienda parteciperà per prima al 45° Annual Health Care Conference di TD Cowen a Boston martedì 4 marzo 2025, dove il Presidente Esecutivo, Presidente e CEO Pravin U. Dugel, MD parteciperà a una chat informale alle 11:50 AM ET.
Successivamente, Ocular parteciperà al Leerink Partners Global Healthcare Conference 2025 a Miami Beach lunedì 10 marzo 2025, con un'altra chat informale programmata per le 10:00 AM ET, che vedrà nuovamente la partecipazione del Dr. Dugel.
Gli investitori possono accedere alle dirette streaming di entrambe le presentazioni tramite la sezione Eventi e Presentazioni nella pagina delle Relazioni con gli Investitori del sito web di Ocular Therapeutix.
Ocular Therapeutix (NASDAQ: OCUL), una compañía biofarmacéutica enfocada en redefinir la experiencia de la retina, ha anunciado su participación en dos importantes conferencias para inversores en marzo de 2025.
La compañía asistirá primero a la 45ª Conferencia Anual de Atención Médica de TD Cowen en Boston el martes 4 de marzo de 2025, donde el Presidente Ejecutivo, Presidente y CEO Pravin U. Dugel, MD participará en una charla informal a las 11:50 AM ET.
Después de esto, Ocular se unirá a la Conferencia Global de Atención Médica de Leerink Partners 2025 en Miami Beach el lunes 10 de marzo de 2025, con otra charla informal programada para las 10:00 AM ET, también con la participación del Dr. Dugel.
Los inversores pueden acceder a las transmisiones en vivo de ambas presentaciones a través de la sección de Eventos y Presentaciones en la página de Relaciones con Inversores del sitio web de Ocular Therapeutix.
Ocular Therapeutix (NASDAQ: OCUL)는 망막 경험을 재정의하는 데 집중하는 생물 의약품 회사로, 2025년 3월에 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 먼저 2025년 3월 4일 화요일 보스턴에서 열리는 TD Cowen 제45회 연례 헬스케어 회의에 참석하며, 이 자리에서 집행 회장이자 CEO인 Pravin U. Dugel, MD가 오전 11:50 ET에 대담에 참여할 예정입니다.
이후 Ocular는 2025년 3월 10일 월요일 마이애미 비치에서 열리는 Leerink Partners 글로벌 헬스케어 회의 2025에 참석하며, 오전 10:00 ET에 또 다른 대담이 예정되어 있으며, 이 또한 Dr. Dugel이 참석합니다.
투자자들은 Ocular Therapeutix 웹사이트의 투자자 관계 페이지에 있는 이벤트 및 발표 섹션을 통해 두 발표의 라이브 웹캐스트에 접근할 수 있습니다.
Ocular Therapeutix (NASDAQ: OCUL), une entreprise biopharmaceutique axée sur la redéfinition de l'expérience rétinienne, a annoncé sa participation à deux importantes conférences pour investisseurs en mars 2025.
L'entreprise assistera d'abord à la 45e Conférence Annuelle de Soins de Santé de TD Cowen à Boston le mardi 4 mars 2025, où le Président Exécutif, Président et CEO Pravin U. Dugel, MD participera à une discussion informelle à 11h50 ET.
Ensuite, Ocular rejoindra la Conférence Mondiale de Soins de Santé de Leerink Partners 2025 à Miami Beach le lundi 10 mars 2025, avec une autre discussion informelle prévue à 10h00 ET, également avec la participation du Dr. Dugel.
Les investisseurs peuvent accéder aux diffusions en direct des deux présentations via la section Événements et Présentations de la page Relations avec les Investisseurs du site Web d'Ocular Therapeutix.
Ocular Therapeutix (NASDAQ: OCUL), ein biopharmazeutisches Unternehmen, das sich auf die Neugestaltung des Retina-Erlebnisses konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 angekündigt.
Das Unternehmen wird zunächst an der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston am Dienstag, den 4. März 2025, teilnehmen, wo der Executive Chairman, Präsident und CEO Pravin U. Dugel, MD um 11:50 Uhr ET an einem informellen Gespräch teilnehmen wird.
Im Anschluss wird Ocular an der Leerink Partners Global Healthcare Conference 2025 in Miami Beach am Montag, den 10. März 2025, teilnehmen, mit einem weiteren informellen Gespräch, das um 10:00 Uhr ET geplant ist und ebenfalls Dr. Dugel featured.
Investoren können die Live-Übertragungen beider Präsentationen über den Bereich Veranstaltungen und Präsentationen auf der Investor Relations-Seite der Ocular Therapeutix-Website abrufen.
- None.
- None.
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in March:
TD Cowen 45th Annual Health Care Conference Presentation Details
Fireside Chat Date: Tuesday, March 4, 2025
Fireside Chat Time: 11:50 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Boston, MA
Leerink Partners Global Healthcare Conference 2025
Fireside Chat Date: Monday, March 10, 2025
Fireside Chat Time: 10:00 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Miami Beach, FL
A live webcast of the fireside chat and presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the TD Cowen Healthcare Conference in 2025?
Who will represent Ocular Therapeutix (OCUL) at the March 2025 investor conferences?
How can investors access Ocular Therapeutix's (OCUL) March 2025 conference presentations?
What is the date and time for Ocular Therapeutix's (OCUL) presentation at the Leerink Partners Conference?
Which investor conferences will Ocular Therapeutix (OCUL) attend in March 2025?
